Oxaliplatin as a radiosensitizing agent in rectal cancer

Sergio Huerta, John Hrom

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The efficacy of oxaliplatin monotherapy against several solid tumors and its relative lack of nephrotoxicity and myelosupression, coupled with results of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer trial, led to a great deal of interest for the implementation of this chemotherapeutic agent in the preoperative setting for the management of adenocarcinoma of the rectum. Despite limited in-vitro and in-vivo data with regard to the radiosensitizing properties of oxaliplatin in rectal cancer, it rapidly entered phase I-III clinical trials. This study reviews the results of these trials and the current status of oxaliplatin as a radiosensitizing agent in the neoadjuvant management of rectal cancer.

Original languageEnglish (US)
Pages (from-to)317-323
Number of pages7
JournalAnti-Cancer Drugs
Volume22
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

oxaliplatin
Radiation-Sensitizing Agents
Rectal Neoplasms
Phase III Clinical Trials
Clinical Trials, Phase I
Leucovorin
Rectum
Fluorouracil
Colonic Neoplasms
Multicenter Studies
Adenocarcinoma

Keywords

  • Abdominoperineal resection
  • cisplatin
  • low anterior resection
  • pathological complete response

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Oxaliplatin as a radiosensitizing agent in rectal cancer. / Huerta, Sergio; Hrom, John.

In: Anti-Cancer Drugs, Vol. 22, No. 4, 04.2011, p. 317-323.

Research output: Contribution to journalArticle

Huerta, Sergio ; Hrom, John. / Oxaliplatin as a radiosensitizing agent in rectal cancer. In: Anti-Cancer Drugs. 2011 ; Vol. 22, No. 4. pp. 317-323.
@article{f01603007bf44b7cbb694138916385d4,
title = "Oxaliplatin as a radiosensitizing agent in rectal cancer",
abstract = "The efficacy of oxaliplatin monotherapy against several solid tumors and its relative lack of nephrotoxicity and myelosupression, coupled with results of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer trial, led to a great deal of interest for the implementation of this chemotherapeutic agent in the preoperative setting for the management of adenocarcinoma of the rectum. Despite limited in-vitro and in-vivo data with regard to the radiosensitizing properties of oxaliplatin in rectal cancer, it rapidly entered phase I-III clinical trials. This study reviews the results of these trials and the current status of oxaliplatin as a radiosensitizing agent in the neoadjuvant management of rectal cancer.",
keywords = "Abdominoperineal resection, cisplatin, low anterior resection, pathological complete response",
author = "Sergio Huerta and John Hrom",
year = "2011",
month = "4",
doi = "10.1097/CAD.0b013e328343e076",
language = "English (US)",
volume = "22",
pages = "317--323",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Oxaliplatin as a radiosensitizing agent in rectal cancer

AU - Huerta, Sergio

AU - Hrom, John

PY - 2011/4

Y1 - 2011/4

N2 - The efficacy of oxaliplatin monotherapy against several solid tumors and its relative lack of nephrotoxicity and myelosupression, coupled with results of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer trial, led to a great deal of interest for the implementation of this chemotherapeutic agent in the preoperative setting for the management of adenocarcinoma of the rectum. Despite limited in-vitro and in-vivo data with regard to the radiosensitizing properties of oxaliplatin in rectal cancer, it rapidly entered phase I-III clinical trials. This study reviews the results of these trials and the current status of oxaliplatin as a radiosensitizing agent in the neoadjuvant management of rectal cancer.

AB - The efficacy of oxaliplatin monotherapy against several solid tumors and its relative lack of nephrotoxicity and myelosupression, coupled with results of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer trial, led to a great deal of interest for the implementation of this chemotherapeutic agent in the preoperative setting for the management of adenocarcinoma of the rectum. Despite limited in-vitro and in-vivo data with regard to the radiosensitizing properties of oxaliplatin in rectal cancer, it rapidly entered phase I-III clinical trials. This study reviews the results of these trials and the current status of oxaliplatin as a radiosensitizing agent in the neoadjuvant management of rectal cancer.

KW - Abdominoperineal resection

KW - cisplatin

KW - low anterior resection

KW - pathological complete response

UR - http://www.scopus.com/inward/record.url?scp=79952991960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952991960&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e328343e076

DO - 10.1097/CAD.0b013e328343e076

M3 - Article

C2 - 21285866

AN - SCOPUS:79952991960

VL - 22

SP - 317

EP - 323

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 4

ER -